Literature DB >> 19644449

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.

Jennifer N Cash1, Carlis A Rejon, Alexandra C McPherron, Daniel J Bernard, Thomas B Thompson.   

Abstract

Myostatin is a member of the transforming growth factor-beta (TGF-beta) family and a strong negative regulator of muscle growth. Here, we present the crystal structure of myostatin in complex with the antagonist follistatin 288 (Fst288). We find that the prehelix region of myostatin very closely resembles that of TGF-beta class members and that this region alone can be swapped into activin A to confer signalling through the non-canonical type I receptor Alk5. Furthermore, the N-terminal domain of Fst288 undergoes conformational rearrangements to bind myostatin and likely acts as a site of specificity for the antagonist. In addition, a unique continuous electropositive surface is created when myostatin binds Fst288, which significantly increases the affinity for heparin. This translates into stronger interactions with the cell surface and enhanced myostatin degradation in the presence of either Fst288 or Fst315. Overall, we have identified several characteristics unique to myostatin that will be paramount to the rational design of myostatin inhibitors that could be used in the treatment of muscle-wasting disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644449      PMCID: PMC2738701          DOI: 10.1038/emboj.2009.205

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  90 in total

1.  Evolutionary trace analysis of TGF-beta and related growth factors: implications for site-directed mutagenesis.

Authors:  C A Innis; J Shi; T L Blundell
Journal:  Protein Eng       Date:  2000-12

2.  Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin.

Authors:  O Hashimoto; N Kawasaki; K Tsuchida; S Shimasaki; T Hayakawa; H Sugino
Journal:  Cell Signal       Date:  2000-08       Impact factor: 4.315

3.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

4.  The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.

Authors:  Thomas B Thompson; Thomas F Lerch; Robert W Cook; Teresa K Woodruff; Theodore S Jardetzky
Journal:  Dev Cell       Date:  2005-10       Impact factor: 12.270

5.  Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle.

Authors:  R Kambadur; M Sharma; T P Smith; J J Bass
Journal:  Genome Res       Date:  1997-09       Impact factor: 9.043

6.  Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand.

Authors:  Stefan Saremba; Joachim Nickel; Axel Seher; Alexander Kotzsch; Walter Sebald; Thomas D Mueller
Journal:  FEBS J       Date:  2007-12-06       Impact factor: 5.542

Review 7.  Myostatin as a therapeutic target for musculoskeletal disease.

Authors:  L Bradley; P J Yaworsky; F S Walsh
Journal:  Cell Mol Life Sci       Date:  2008-07       Impact factor: 9.261

8.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

9.  Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.

Authors:  Maya Mouler Rechtman; Alex Nakaryakov; Keren E Shapira; Marcelo Ehrlich; Yoav I Henis
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate.

Authors:  Sally L Mellor; Emma M A Ball; Anne E O'Connor; Jean-François Ethier; Mark Cranfield; Jacqueline F Schmitt; David J Phillips; Nigel P Groome; Gail P Risbridger
Journal:  Endocrinology       Date:  2003-06-26       Impact factor: 4.736

View more
  67 in total

1.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

2.  Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice.

Authors:  Kentaro Takayama; Tomo Asari; Mariko Saitoh; Kei Nirasawa; Eri Sasaki; Yoshimi Roppongi; Akari Nakamura; Yusuke Saga; Takahiro Shimada; Hiroaki Ikeyama; Akihiro Taguchi; Atsuhiko Taniguchi; Yoichi Negishi; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2019-05-28       Impact factor: 4.345

3.  Crystal structure of human GDF11.

Authors:  Anil K Padyana; Bhamini Vaidialingam; David B Hayes; Priyanka Gupta; Michael Franti; Neil A Farrow
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-02-16       Impact factor: 1.056

Review 4.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

5.  Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity.

Authors:  Erich J Goebel; Richard A Corpina; Cynthia S Hinck; Magdalena Czepnik; Roselyne Castonguay; Rosa Grenha; Angela Boisvert; Gabriella Miklossy; Paul T Fullerton; Martin M Matzuk; Vincent J Idone; Aris N Economides; Ravindra Kumar; Andrew P Hinck; Thomas B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-17       Impact factor: 11.205

6.  Myostatin regulates pituitary development and hepatic IGF1.

Authors:  Wioletta Czaja; Yukiko K Nakamura; Naisi Li; Jennifer A Eldridge; David M DeAvila; Thomas B Thompson; Buel D Rodgers
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-03-19       Impact factor: 4.310

Review 7.  The DAN family: modulators of TGF-β signaling and beyond.

Authors:  Kristof Nolan; Thomas B Thompson
Journal:  Protein Sci       Date:  2014-06-02       Impact factor: 6.725

8.  Structure of Gremlin-2 in Complex with GDF5 Gives Insight into DAN-Family-Mediated BMP Antagonism.

Authors:  Kristof Nolan; Chandramohan Kattamuri; Scott A Rankin; Randy J Read; Aaron M Zorn; Thomas B Thompson
Journal:  Cell Rep       Date:  2016-08-11       Impact factor: 9.423

9.  Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Authors:  Chandramohan Kattamuri; David M Luedeke; Kristof Nolan; Scott A Rankin; Kenneth D Greis; Aaron M Zorn; Thomas B Thompson
Journal:  J Mol Biol       Date:  2012-10-09       Impact factor: 5.469

10.  Cytotoxic aggregation and amyloid formation by the myostatin precursor protein.

Authors:  Carlene S Starck; Andrew J Sutherland-Smith
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.